Ocular Therapeutix, Inc (OCUL) — 8-K Filings

8-K Filings (21)

• 8-K Filing — May 5, 2026
• Ocular Therapeutix Files 8-K — Dec 18, 2025 Risk: medium
  Ocular Therapeutix, Inc. filed an 8-K on December 18, 2025, reporting an event under "Other Events." The filing does not contain specific details about the even
• 8-K Filing — Dec 5, 2025
• Ocular Therapeutix Files 8-K: Other Events Reported — Sep 30, 2025 Risk: medium
  Ocular Therapeutix, Inc. filed an 8-K on September 30, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these ev
• Ocular Therapeutix Files 8-K on Operations and Financials — Aug 5, 2025 Risk: low
  Ocular Therapeutix, Inc. filed an 8-K on August 5, 2025, reporting on its results of operations and financial condition, as well as financial statements and exh
• Ocular Therapeutix Files 8-K: Director Changes and Bylaw Amendments — Jun 11, 2025 Risk: medium
  Ocular Therapeutix, Inc. filed an 8-K on June 11, 2025, reporting several key events. These include the departure of director Dr. Robert J. Langer, the election
• Ocular Therapeutix Files 8-K on Financials — May 5, 2025 Risk: low
  Ocular Therapeutix, Inc. filed an 8-K on May 5, 2025, reporting on its results of operations and financial condition, as well as filing financial statements and
• Ocular Therapeutix Files 8-K on Financials — Mar 3, 2025 Risk: low
  Ocular Therapeutix, Inc. filed an 8-K on March 3, 2025, reporting on its results of operations and financial condition. The filing also includes financial state
• Ocular Therapeutix Announces Executive and Board Changes — Feb 14, 2025 Risk: medium
  Ocular Therapeutix, Inc. announced on February 11, 2025, changes in its board of directors and executive compensation. Specifically, Dr. Jonathan T. Miller resi
• Ocular Therapeutix Files 8-K on Financials — Nov 14, 2024 Risk: low
  Ocular Therapeutix, Inc. filed an 8-K on November 14, 2024, reporting on its results of operations and financial condition. The filing includes financial statem
• Ocular Therapeutix Appoints New CMO, Director — Oct 9, 2024 Risk: low
  Ocular Therapeutix, Inc. announced on October 4, 2024, the appointment of Dr. Jonathan T. Miller as Chief Medical Officer and the election of Ms. Amy T. Peterso
• Ocular Therapeutix CFO Departs, New CFO Appointed — Sep 3, 2024 Risk: medium
  Ocular Therapeutix, Inc. announced on August 29, 2024, the departure of its Chief Financial Officer, Jonathan M. Miller, effective September 6, 2024. The compan
• Ocular Therapeutix Files 8-K on Operations and Financials — Aug 7, 2024 Risk: low
  Ocular Therapeutix, Inc. filed an 8-K on August 7, 2024, to report on its results of operations and financial condition, and to file financial statements and ex
• Ocular Therapeutix Reports Director/Officer Changes & Governance Updates — Jun 14, 2024 Risk: medium
  Ocular Therapeutix, Inc. filed an 8-K on June 14, 2024, reporting on several key events as of June 12, 2024. These include the departure of directors or certain
• Ocular Therapeutix Reports Exit/Disposal Costs — Jun 3, 2024 Risk: medium
  Ocular Therapeutix, Inc. reported on May 29, 2024, that it is incurring costs associated with exit or disposal activities. The company, incorporated in Delaware
• Ocular Therapeutix Files 8-K on Financials — May 7, 2024 Risk: low
  Ocular Therapeutix, Inc. filed an 8-K on May 7, 2024, reporting on its financial condition and results of operations. The filing includes financial statements a
• Ocular Therapeutix Appoints New Chief Medical Officer — Apr 18, 2024 Risk: low
  Ocular Therapeutix, Inc. announced on April 14, 2024, the appointment of Dr. Jonathan T. Miller as Chief Medical Officer. Dr. Miller previously served as the co
• Ocular Therapeutix Sells DEXTENZA to Bausch & Lomb for $120M — Mar 29, 2024 Risk: medium
  Ocular Therapeutix, Inc. announced on March 28, 2024, that it has entered into a definitive agreement to sell its Ocular surface disease assets, including the p
• Ocular Therapeutix Files 8-K on Financials — Mar 11, 2024 Risk: low
  Ocular Therapeutix, Inc. filed an 8-K on March 11, 2024, reporting on its results of operations and financial condition, as well as filing financial statements
• OCULAR THERAPEUTIX Reports Material Agreement, Equity Sales, Officer Comp Changes — Feb 22, 2024 Risk: medium
  OCULAR THERAPEUTIX, INC. filed an 8-K on February 22, 2024, reporting events from February 20, 2024. The filing indicates entry into a material definitive agree
• OCULAR THERAPEUTIX Files 8-K for Routine Administrative Update — Jan 25, 2024
  OCULAR THERAPEUTIX, INC. filed an 8-K on January 25, 2024, to report an "Other Event." This filing primarily serves to update administrative information, such a

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX